​​​​​​NIJMEGEN, THE NETHERLANDS / ACCESSWIRE / December 9, 2019 / Xenikos B.V.:

75% (9/12) patients achieved clinical response by day 28; five patients achieved complete remission
6-month overall survival was 75% in the EAP cohort versus 29% in a historical control group
Plasma levels of the biomarker citrulline were correlated with the clinical response to T-Guard in SR-aGVHD patients with GI involvement
Consistent with Phase 1/2 testing, T-Guard was well tolerated and significantly improved patient outcome compared to historical controls

The Dutch company Xenikos B.V., which develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, reports today data from an expanded access program (EAP) using T-Guard to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients following allogeneic stem cell transplantation. These data are being presented later today at the 61st annual meeting of the American Society of Hematology in Orlando, FL, by Walter van der Velden, MD, PhD from Radboud University Medical Center in Nijmegen, the Netherlands. The poster presentation entitled "Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard(R)) for the Treatment of Steroid-Refractory Acute GVHD" can be viewed on the Xenikos website, and the abstract is available here.

In this program, conducted in the Netherlands, Xenikos' anti-CD3/anti-CD7 immunotoxin therapy T-Guard was given as second- or third-line treatment to 12 high-risk adult patients with grade II-IV SR-aGVHD following allogeneic stem cell transplantation for a myeloid or lymphoid malignancy.

By treatment day 28, 75% of patients had achieved a clinical response, with five of these nine patients achieving complete remission. In addition, the 6-month and 1-year overall survival rate was 75% and 58%, respectively. These outcomes are significantly higher than historical controls and are similar to the results of the Phase 1/2 clinical trial. T-Guard appeared to be well tolerated and no significant infusion-related reactions were recorded.

"More effective therapies for steroid-refractory acute graft-versus-host disease are urgently needed," said Dr. Van der Velden. "The results of the Phase 1/2 clinical trial and now in the expanded access program show highly promising response rates, including complete remission and overall survival rates that are substantially higher than historical controls. I believe that T-Guard may represent a paradigm shift in how we treat patients with this potentially fatal condition."

"We're highly encouraged by the positive results of the expanded access program with T-Guard," added Dr. Ypke van Oosterhout, Chief Executive Officer of Xenikos. "We are now recruiting patients for our US-based Phase 3 registration trial, marking the next step in taking T-Guard to market. Importantly, T-Guard, which is administered as a single one-week treatment, was previously shown to promote swift restoration of the patient's immune system, reducing the risk of infection and relapse. We believe that T-Guard is quite promising in terms of treating patients with this devastating condition, and we look forward to entering the final phase of development."

Citrulline levels are correlated with the clinical response to T-Guard

Dr. Van der Velden and his group also analyzed the relationship between plasma levels of citrulline (a biomarker of enterocytes, which play a role in healthy intestinal function) and the response to T-Guard in a subset of SR-aGVHD patients with GI involvement, including patients from both the Phase 1/2 study and the expanded access program. Their preliminary results show that the patients' citrulline levels were extremely low prior to the start of T-Guard treatment and increased significantly in the patients who achieved complete remission by day 28, indicating that plasma citrulline may serve as a robust prognostic biomarker.

T-Guard: Helping reset the body's immune system

T-Guard is designed to safely and swiftly reset the body's immune system in life-threatening T cell‒mediated conditions, including transplant-related rejection, acute solid-organ rejection, and severe autoimmune disease. T-Guard consists of a unique combination of toxin-conjugated monoclonal antibodies that target CD3 and CD7 molecules on T cells and NK cells. Preclinical and early clinical testing have shown that T-Guard can specifically identify and eliminate mature T cells and NK cells with minimal treatment-related side effects. Importantly, T-Guard's action is short-lived, thereby significantly reducing the patient's vulnerability to opportunistic infections compared to currently available therapies. Xenikos recently completed a Phase 1/2 study for the second-line treatment of SR-aGVHD in patients following hematopoietic stem cell transplantation, showing that just one week of T-Guard treatment triggered a strong clinical response and doubled the 6-month overall survival rate; these results were published in the peer-reviewed journal Biology of Blood and Marrow Transplantation. T-Guard has been approved by the US FDA as an Investigational New Drug (IND) and Xenikos is now recruiting patients for a US-based Phase 3 registration trial (NCT04128319) evaluating T-Guard for the treatment of SR-aGVHD following allogeneic stem cell transplantation. T-Guard has been granted Orphan Drug Designation status in both the EU and the US.

Acute graft-versus-host disease

Following allogeneic stem cell transplantation, most patients have a high risk of developing graft-versus-host disease (GVHD), and this risk increases considerably in older patients. With GVHD, the donor's immune cells attack the patient's cells. Acute GVHD occurs early after transplantation and can be relatively mild or quite severe, even life-threatening, if not treated. Although GVHD can often be treated successfully with steroids, few options are available if the disease progresses or becomes resistant to steroid treatment, and the long-term survival of patients with steroid-refractory acute GVHD is less than 20%, highlighting the urgent need for effective therapies.

About Xenikos

Xenikos develops innovative immunotherapies based on conjugated antibodies. This novel therapeutic approach helps reset the immune system in patients who have a severe immune disease or have developed post-transplantation rejection. Xenikos is now recruiting patients for a US-based Phase 3 registration trial (NCT04128319) with its flagship product, T-Guard(R), to treat steroid-refractory acute GVHD following allogeneic stem cell transplantation.

For more information, visit us at www.xenikos.com.

Follow us on LinkedIn.

For further information, please contact:

Corporate contact:
Media contact:

Xenikos B.V.
Ypke van Oosterhout, PhD
Chief Executive Officer
Phone: +31 24 3000100
Mobile: +31 6 11017611
Email: y.vanoosterhout@xenikos.com
MC Services AG
Dr. Solveigh Mähler
Phone: +49 211 529 252 19
Mobile: +49 171 656 382 74
Email: solveigh.maehler@mc-services.eu

 
For U.S. inquiries:
Laurie Doyle
Phone: +1 339 832 0752
Email: laurie.doyle@mc-services.eu

SOURCE: Xenikos B.V. 

ReleaseID: 569543

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

PG&E Corporation (NYSE:PCG)

Class Period: December 11, 2018 – October 11, 2019

Deadline: December 24, 2019
For more info: www.bgandg.com/pcg

The Complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) PG&E's purportedly enhanced wildfire prevention and safety protocols and procedures were inadequate to meet the challenges for which they were ostensibly designed; (2) as a result, PG&E was unprepared for the rolling power cuts the Company implemented to minimize wildfire risk; and (3) as a result, PG&E's public statements were materially false and misleading at all relevant times.

Uniti Group Inc. (NASDAQ:UNIT)

Class Period: April 20, 2015 – February 15, 2019

Deadline: December 30, 2019
For more info: www.bgandg.com/unit

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Uniti's financial results were not sustainable because its customer Windstream Holdings, Inc. had defaulted on its unsecured notes; and (2) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Twitter, Inc. (NYSE:TWTR)

Class Period: August 6, 2019 – October 23, 2019

Deadline: December 30, 2019
For more info: www.bgandg.com/twtr

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) while Twitter represented that it "fixed" certain issues relating to user choice settings designed to target advertising were not working as intended; (2) the changes implemented to fix these issues adversely affected Twitter's ability to target advertising, including the targeting of advertising through its Mobile App Promotion ("MAP") product, which caused a material decline in advertising revenue; and (3) as a result, Twitter's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 569484

OTTAWA, ON / ACCESSWIRE / December 9, 2019 / The Native Women's Association of Canada (NWAC) will have a strong presence at COP25, the 25th UN Climate Change Conference, which is designed to take the next steps in the climate change process, in advance of full operationalization of the Paris Climate Change Agreement in 2020. Among the focus areas up for discussion are Indigenous peoples and gender.

"NWAC's presence at COP25 is crucial. We have been, and continue to be, very engaged in climate action at both the domestic and international levels, as well as advancing gender balance and ensuring the voices of Indigenous women are heard in international discussions on climate change," says President Lorraine Whitman.

On the domestic front, NWAC conducts research and provides policy papers to the federal government on matters related to renewable energies and the need for increased representation of Indigenous women in low-carbon economic sectors. "We have been advocating for a number of environment-related issues, including the need to regulate toxic substances, which have cumulative effects on Indigenous women and children," says Lynne Groulx, NWAC CEO.

To enhance its input on environmental files, NWAC is developing a low-carbon toolkit for Indigenous women who want to start or grow businesses that contribute to climate change mitigation and/or adaptation.

NWAC is also making a strong, visible presence internationally – participating in meetings held under the United Nations Framework Convention on Climate Change and the Intergovernmental Panel on Climate Change. Through these international forums, NWAC advocates for the rights and interests of Indigenous women as they relate to the environment in general and climate change in particular.

As an example, by contributing to the Local Communities and Indigenous Peoples Platform, NWAC is able to advance gender balance and ensure the voices of Indigenous women are heard in international discussions on climate change.

"Climate change affects all humankind. When taking action to address this important issue, the respective obligations on the rights of indigenous peoples and local communities must be respected, promoted and considered. After all, Indigenous people are stewards of the land, and Indigenous women are the life-givers and caretakers of all life," says President Whitman. "We look forward to contributing to the dialogue at COP25."

-30-

For media inquiries: Joan Weinman, 613-294-5679, joanweinman@rogers.com

SOURCE: The Native Women's Association of Canada

ReleaseID: 569541

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

iRobot Corporation (NASDAQ:IRBT)

Class Period: November 21, 2016 – October 22, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/irbt

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) iRobot's explosive growth was not based on increased demand, expanding margins, and product innovations, as it claimed, but rather based on channel stuffing; (2) the Company attempted to conceal its actions by acquiring its distributors in Europe and Asia; (3) these acquisitions were designed to clean up the company's global inventory and mask falling demand; and (4) as a result, iRobot's public statements were materially false and misleading at all relevant times.

Zendesk, Inc. (NASDAQ:ZEN)

Class Period: February 6, 2019 – October 1, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/zen

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zendesk's clients had been subject to data breaches dating back to 2016; (2) Zendesk was experiencing slowing demand for its SaaS offerings, particularly in Germany, the U.K. and Australia, due in large part to political uncertainty and China trade issues; (3) for the forgoing reasons, Zendesk's business metrics and financial prospects were not as strong as represented during the Class Period; and (4) as a result, Zendesk's public statements were materially false and misleading at all relevant times.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)

Class Period: March 11, 2019 – September 17, 2019

Deadline: December 23, 2019
For more info: www.bgandg.com/zyne

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 569483

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Levi & Korsinsky, LLP filed an amended complaint against Bloom Energy Corporation ("Bloom Energy") (NYSE:BE) and its officers, directors, and underwriters on November 4, 2019. Levi & Korsinsky filed the amended complaint in its ongoing class action lawsuit pending in the United States District Court for the Northern District of California.

On September 3, 2019, Judge William H. Orrick appointed Levi & Korsinsky as lead counsel for the class action lawsuit. The firm has been actively compiling a case against Bloom Energy by, among other things, reviewing the company's public statements and contacting whistleblowers with evidence of fraud.

If you or someone you know can assist Levi & Korsinsky's active case against Bloom Energy, please contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

To get more information or view copy of Levi & Korsinsky's amended complaint, go to:

https://www.zlk.com/pslra-1/bloom-energy-corporation-loss-form

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 569542

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Domo, Inc. ("Domo" or the "Company") (NASDAQ:DOMO) and certain of its officers, on behalf of shareholders who purchased Domo securities (1) from June 26, 2018 through September 5, 2019, inclusive (the "Class Period"); or (2) pursuant and/or traceable to the Company's registration statement and related prospectus issued in connection with the Company's initial public offering ("IPO" or the "Offering") commenced on or about June 29, 2018. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/domo.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Domo was experiencing weakness in its enterprise and international businesses; (2) Domo's billings growth had dramatically slowed; (3) all of the foregoing was reasonably likely to have a material negative impact on the Company's financial results; and (4) as a result, Domo's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/domo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Domo you have until December 16, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 569482

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fiat Chrysler Automobiles N.V. ("Fiat Chrysler" or the "Company") (NYSE:FCAU) and certain of its officers, on behalf of shareholders who purchased Fiat Chrysler securities between February 26, 2016 and November 20, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/fcau.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Fiat employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with International Union, United Automobile, Aerospace and Agricultural Implement Workers of America; (2) high-ranking Fiat official were aware of and authorized the scheme; and (3) due to the foregoing, defendants' statements about Fiat's receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/fcau or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Fiat Chrysler you have until January 31, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 569492

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Prudential Financial, Inc. ("Prudential" or the "Company") (NYSE:PRU) and certain of its officers, on behalf of shareholders who purchased Prudential securities between February 15, 2019 and August 2, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/pru.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's reserve assumptions failed to account for adversely developing mortality experience in its Individual Life business segment; (2) the Company was not over-reserved, but instead, its reported reserves, particularly for the Individual Life business segment, were insufficient to satisfy its future policy benefits liabilities; (3) the Company had materially understated its liabilities and overstated net income as a result of flawed assumptions in calculating mortality experience; and (4) as a result, Prudential's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/pru or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Prudential you have until January 27, 2020 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 569491

NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ADTRAN, Inc. ("ADTRAN" or the "Company") (NASDAQ:ADTN) and certain of its officers, on behalf of shareholders who purchased ADTRAN securities between February 28, 2019 and October 9, 2019, (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:www.bgandg.com/adtn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) there were material weaknesses in the Company's internal control over financial reporting; (2) as a result, certain E&O reserves had been improperly reported; (3) as a result, the Company's financial results for certain periods were misstated; (4) there would be a pause in shipments to the Company's Latin American customer; and (5) as a result, ADTRAN's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/adtn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ADTRAN you have until December 16, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 569481

TAMPA, FL / ACCESSWIRE / December 9, 2019 / Advanzeon Solutions, Inc. (OTC PINK:CHCR)("Advanzeon") announced today that its wholly-owned subsidiary, Pharmacy Value Management Solutions, Inc. (collectively, the "Company"), has hired Mr. John Argiro to serve as its Chief Marketing Officer, effective immediately. In this position, Mr. Argiro will concentrate on supporting and expanding the Company's SleepMaster Solutions™ brand.

Mr. Argiro comes to the Company with a proven track record in healthcare and a substantial, well-established and loyal book of business. Founding "The Argiro Group" in 2001 and focusing primarily on the labor union market, Mr. Argiro established a reputation among national labor leaders as the "go-to" healthcare leader for providing their members with top-quality, innovative healthcare products and programs at affordable prices. In his role as the Company's Chief Marketing Officer, Mr. Argiro affords the Company the ability to immediately access two of his largest accounts with a membership population in excess of two million, and more thereafter. He anticipates bringing significantly more business to the Company, commencing in Q1 of 2020.

Clark A. Marcus, the Company's Chairman and Chief Executive Officer, stated, "Having known John for in excess of 20 years and witnessing firsthand the respect the labor industry affords him, I am confident that John will more than exceed expectations in expanding the Company's already robust portfolio in the healthcare labor market. His relationship with notable industry leaders is unsurpassed. I am certain that John will become a valuable asset to the Company in terms of maturing already in place contracts the Company has in the labor industry and expanding our labor footprint nationally. "

Mr. Argiro added, "It's a pleasure to be able to apply my knowledge of and relationships in the health industry to my new role with SleepMaster Solutions™. I have no doubt that the SleepMaster Solutions™ program will be a welcome addition to my clients' current healthcare plans and a program that can be implemented almost immediately — it is cost effective, cost saving and a program that we all know will literally save lives. I know my clients recognize this value and will want to bring such a program to their membership immediately."

Mr. Argiro is a former United States Marine and veteran of Operation Desert Storm. In addition, he is a board consultant for America's Agenda, a Washington D.C.-based health care company with a board membership consisting of a significant number of, among others, national labor leaders, whose imperative is to lower the cost of health care nationwide. Mr. Argiro also served on the European Congress of Union's Health Care Advisory Committee.

About Advanzeon Solutions, Inc.

Advanzeon Solutions, Inc. (OTC PINK:CHCR) through its subsidiary, owns and operates the nation's most complete sleep apnea program, SleepMaster Solutions™ (the "Program"). Headquartered in Tampa, Florida, the Company's Program is available in all fifty states and Washington D.C. The Program focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches that address both the specific needs of clients and changing healthcare industry demands. For more information, visit our website at www.advanzeon.com.

Safe Harbor Statement

This press release contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, results of operations, plans and objectives. In some cases, you may identify forward-looking statements by words such as "may," "should," "plan," "intend," "potential," "continue," "believe," "expect," "predict," "anticipate" and "estimate," the negative of these words or other comparable words. These statements are only predictions. One should not place undue reliance on these forward-looking statements. The forward-looking statements are qualified by their terms and/or important factors, many of which are outside the Company's control, involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made. The forward-looking statements are based on the Company's beliefs, assumptions and expectations of our future performance, taking into account information currently available to the Company. These beliefs, assumptions and expectations can change as a result of many possible events or factors, not all of which are known to the Company. Neither the Company nor any other person assumes responsibility for the accuracy or completeness of these statements. The Company will update the information in this press release only to the extent required under applicable securities laws. If a change occurs, the Company's business, financial condition, liquidity and results of operations may vary materially from those expressed in the aforementioned forward-looking statements.

Public Relations Contact:

Brianna Bujnowski
Crank Communications
407-830-7312
brianna@crankcommunications.com

Investor Relations Contact:

Philip Pulver
Communications Director
509-607-7229
ppulver@sleepmastersolutions.com
www.AdvanzeonShareholders.com

SOURCE: Advanzeon Solutions, Inc.

ReleaseID: 569540